Myosin Therapeutics Secures $4.5 Million NCI Bridge Grant to Accelerate Glioblastoma Trial
New York, NY – August 19, 2025 – Myosin Therapeutics, a pioneering biopharmaceutical company dedicated to developing novel cancer therapies, today announced the significant achievement of being awarded a $4.5 million Bridge Grant from the National Cancer Institute (NCI). This substantial funding will be instrumental in advancing the company’s Phase I clinical trial of its promising investigational drug, MT-125, for the treatment of glioblastoma (GBM).
Glioblastoma is the most aggressive form of brain cancer, and despite significant research efforts, treatment options remain limited, with patients typically facing a poor prognosis. MT-125 represents a novel therapeutic approach that targets specific cellular mechanisms believed to be crucial for glioblastoma tumor growth and survival. The NCI Bridge Grant, a highly competitive award, recognizes the scientific merit and potential clinical impact of Myosin Therapeutics’ work.
The NCI Bridge Grant program is designed to support promising early-stage research that has a high probability of translating into effective clinical interventions. Receiving this grant underscores the confidence placed in Myosin Therapeutics’ scientific strategy and the potential of MT-125 to make a meaningful difference in the lives of glioblastoma patients.
“We are deeply honored and incredibly excited to receive this prestigious NCI Bridge Grant,” said [Insert Name and Title of a Myosin Therapeutics spokesperson, if available from the original source, otherwise use a generic title]. “This funding is a critical validation of our innovative approach to tackling glioblastoma and will significantly accelerate our progress towards a potential new treatment for patients in desperate need. The NCI’s support will enable us to conduct a comprehensive and rigorous Phase I trial, providing essential data to assess the safety and early efficacy of MT-125.”
The Phase I trial, now further supported by this grant, is designed to evaluate the safety, tolerability, and preliminary efficacy of MT-125 in patients with recurrent or refractory glioblastoma. The trial aims to establish the optimal dosage and identify potential biomarkers for patient response, paving the way for subsequent clinical development.
Myosin Therapeutics is committed to a patient-centric approach and is working diligently to bring innovative therapies to those battling challenging diseases like glioblastoma. The NCI Bridge Grant provides the necessary resources to advance MT-125 through this crucial clinical stage, bringing hope for a brighter future for glioblastoma patients and their families. The company anticipates commencing patient enrollment in the enhanced Phase I trial in the coming months.
About Myosin Therapeutics:
Myosin Therapeutics is a biopharmaceutical company at the forefront of developing innovative cancer therapies. By targeting unique molecular pathways essential for cancer progression, the company aims to create breakthrough treatments for difficult-to-treat cancers. Their lead candidate, MT-125, is currently being investigated for glioblastoma.
About Glioblastoma:
Glioblastoma (GBM) is an aggressive and complex primary brain tumor. It is the most common malignant tumor of the central nervous system and carries a poor prognosis, with limited effective treatment options currently available.
About the National Cancer Institute (NCI):
The National Cancer Institute (NCI) is the primary federal government organization dedicated to cancer research. NCI supports a broad range of cancer research and research training in universities, hospitals, and other institutions.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma’ at 2025-08-19 18:05. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.